Перейти к основному содержанию
Brukinsa (Zanubrutinib) 80 mg – Targeted Therapy for Blood Cancers  Brukinsa (Zanubrutinib) - Macrocare Health Blog

Brukinsa (Zanubrutinib) 80 mg – Targeted Therapy for Blood Cancers Brukinsa (Zanubrutinib)

Brukinsa (Zanubrutinib) is a targeted therapy used to treat certain blood cancers and lymphomas. It works by blocking specific pathways that help cancer cells grow and survive.

 

What is Brukinsa (Zanubrutinib)?

Brukinsa belongs to a class of medications known as Bruton's Tyrosine Kinase (BTK) Inhibitors.

BTK plays an important role in the growth and survival of certain cancerous lymphocytes. Brukinsa works by:

  • Blocking cancer cell growth signals
  • Reducing abnormal cell proliferation
  • Helping improve disease control

In simple terms:
It targets a key pathway that certain blood cancers depend on for growth.

 

Indications

Brukinsa (Zanubrutinib) is used in:

  • Certain types of lymphomas
  • Chronic Lymphocytic Leukemia (CLL) in selected cases
  • Other blood cancers according to treatment protocols

 

Dosage and Administration

  • Standard dose: 80 mg according to the treatment protocol
  • Taken orally
  • Once or twice daily depending on the treatment plan
  • Should be taken exactly as prescribed by the physician

 

Common Side Effects

May include:

  • Low blood cell counts
  • Fatigue
  • Mild bruising or bleeding
  • Diarrhea
  • Mild infections
  • Muscle or joint pain

Regular medical monitoring is important during treatment.

 

Monitoring During Treatment

Patients on Brukinsa (Zanubrutinib) require:

  • Regular complete blood count (CBC) monitoring
  • Monitoring for signs of infection or bleeding
  • Assessment of treatment response
  • Evaluation of overall health status

 

Availability & How to Access Treatment

Brukinsa (Zanubrutinib) is available through Macrocare’s approved partners.

You can now request and access the medication easily through us.

WhatsApp contact for medication requests:
Click here

 

Brukinsa (Zanubrutinib) Brukinsa (Zanubrutinib) 80 mg is a targeted therapy for blood cancers and lymphomas that works by blocking cancer cell growth signals and helping improve disease control.

 

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.

 

Другие статьи

Введите номер мобильного телефона

Пожалуйста, укажите ваш номер телефона, чтобы мы могли связаться с вами и узнать о вашей проблеме со здоровьем.

Конфиденциальность защищена: ваша медицинская и личная информация хранится полностью конфиденциально и защищена с использованием отраслевых стандартов защиты.

СВЯЗАТЬСЯ С НАМИ

Свяжитесь с нами

Пожалуйста, укажите ваш номер телефона, чтобы мы могли связаться с вами и узнать о вашей проблеме со здоровьем.